Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGASYS ± lamivudine in HBeAg-negative chronic hepatitis B (Italy Phase 3)
2004-002985-39Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of peginterferon alfa-2a in Chronic hepatitis B (CHB) (3 arms), sponsored by Roche. Primary endpoint: Virological response at end of treatment and follow-up. Started Sep 2005; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
Chronic hepatitis B (CHB)
Beyond the preview
Go deeper on 2004-002985-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002985-39.